GSK plc · LSE:GSK

GSK — GlaxoSmithKline — ATS Analyst and Investor Event 2013

9 slides from GSK's conference presentation, May 21, 2013

  1. Slide 1: ATS Analyst and Investor Event

    ATS Analyst and Investor Event Tuesday 21st May 2013 ATS Analyst and Investor Event Darrell Baker, SVP & Head, Global Respiratory Franchise Tuesday 21st May 2013 Darrell Baker, SVP, Head Global Respiratory Franchise 1

  2. Slide 2: Significant progress in respiratory portfolio in 2013; data at ATS demonstrates research breadth

    We have made significant progress in our respiratory portfolio in 2013; data at ATS demonstrates research breadth ANOROTM for COPD BREOTM for COPD ANOROTM for COPD RELVARTM for asthma and COPD filed in EU and Japan approved in US filed in US filed in EU and Japan BREOTM for COPD filed in US 2012 201

  3. Slide 3: BREO ELLIPTA gains US approval for the treatment of COPD

    Significant milestone achieved: BREO™ ELLIPTA™ gains US approval for the treatment of COPD In the US, BREO™ ELLIPTA™ is approved as a combination inhaled corticosteroid/long-acting beta2-adrenergic agonist (ICS/LABA) ” (FF/VI 100/25 mcg) indicated for the long-term, once-daily, maintenance treatment

  4. Slide 4: Further data at ATS demonstrates depth of FF/VI research

    Further data at ATS demonstrates depth of FF/VI research Filings Asthma COPD US Additional PhIII study ongoing Approved BREOTM EU / Japan  Filed RELVARTM Filed RELVARTM Once a day Data at ATS: ICS/LABA (FF/VI) Phase IIIb RELVARTM/BREOTM versus SERETIDETM/ADVAIRM in COPD – pooled analysis Once-Dai

  5. Slide 5: Fluticasone furoate mono on track to file in 2013, commencing with US and Japan

    Fluticasone furoate mono on track to file in 2013, commencing with US and Japan; ATS data aids understanding of response in asthma Once a day Data at ATS: ICS mono (FF mono) PhIIIa study of FF 50mcg monotherapy versus placebo in asthma Studies at 100 & 200mcg doses contained within FF/VI package pre

  6. Slide 6: ANORO ELLIPTA filings in 2013

    ANOROTM ELLIPTATM filings in 2013 Once a day Filings COPD LAMA/LABA US  Filed Dec 2012 (UMEC/VI) EU  Filed Jan 2013 Japan  Filed Apr 2013 Data at ATS: Three pivotal efficacy PhIIIa studies ANOROTM ELLIPTATM is the proposed brand name for UMEC/VI and is not yet approved. 6

  7. Slide 7: PhIII data presented at ATS supports filings of ANORO ELLIPTA and umeclidinium mono

    PhIII data presented at ATS supports the filings of ANOROTM ELLIPTATM and umeclidinium mono Efficacy based on trough FEV1 at end of treatment PhIIIa study of ANOROTM (125/25mcg) PhIIIa study of ANOROTM (62.5/25mcg) Phase IIIa study of ANOROTM versus TIO versus individual components versus individual

  8. Slide 8: Umeclidinium mono filings supported by ANORO ELLIPTA registration package data

    Umeclidinium mono filings supported by data from the ANOROTM ELLIPTATM registration package Once a day Filings COPD LAMA mono US  Filed April 2013 (UMEC mono) EU  Filed April 2013 ROW Planned during the course of 2013 Data at ATS: Ph IIIa UMEC mono versus placebo in COPD 8

  9. Slide 9: We continue to progress our Respiratory portfolio across varied mechanisms of action

    We continue to progress our Respiratory portfolio across varied mechanisms of action ICS/ LAMA/ ICS/ Anti- SABA ICS LABA LAMA MABA p38 FLAP LABA LABA LAMA IL 5            Company 1     Company 2    Company 3      Company 4     Company 5       Company 6  £2.3bn: resc

GlaxoSmithKline — ATS Analyst and Investor Event 2013 on 6ix